15 June 2016
SpeeDx ResistancePlus MG featured in GenomeWeb article
SpeeDx are featured in a great article in GenomeWeb discussing Mycoplasma genitalium, and the antibiotic resistance status of this significant sexually transmitted...
2 June 2016
SpeeDx establishes European subsidiary
The establishment of a European subsidiary company, SpeeDx Limited, headquartered in the London Bioscience Innovation Centre, will support the future...
20 April 2016
ResistancePlus™ MG featured in Medical Laboratory Observer
Dr. Elisa Mokany, SpeeDx’ co-founder and VP of R&D, is featured in an editorial article on Mycoplasma genitalium. The article...
8 April 2016
SpeeDx to Feature PlexPCR® and ResistancePlus® Tests on M. genitalium at ECCMID
Sydney, Australia (April 8, 2016) – SpeeDx Pty, Ltd. today announced that it will feature its PlexPCR® for detection of infectious...
21 March 2016
SpeeDx Announces Distribution Agreement for PlexPCR® and ResistancePlus® Molecular Diagnostics Products with Goffin Molecular Technologies
– Goffin’s distribution channels will allow broader availability and accessibility of SpeeDx diagnostics in the Benelux market – SYDNEY, AUSTRALIA–(March 21,...
1 December 2015
SpeeDx is featured in Austrade’s Success Stories
Austrade’s Success Stories article highlights our focus in tackling the growing threat of antimicrobial resistance using precision medicine. SpeeDx develops...